In brief
A study from the Garvan Institute of Medical Research in Australia has identified the protein CDK1 as a possible biomarker for predicting how estrogen receptor‑positive breast cancers respond to CDK4/6 inhibitors, a common targeted drug class. The analysis of more than 400 biopsy samples showed that elevated CDK1 activity tracks with more aggressive tumors and worse survival rates. While the findings require confirmation in larger clinical trials, they point toward personalized treatment plans and potential future therapies that target CDK1.
In a recent study published in Advanced Science, Australian researchers from the Garvan Institute of Medical Research announced that the activity level of the protein cyclin‑dependent kinase 1 (CDK1) could be used to predict which estrogen receptor‑positive (ER+) breast cancers will respond to CDK4/6 inhibitor therapy. The announcement came on Friday when the institute released a statement following the study’s results, which analyzed more than 400 breast cancer biopsy samples.
The research focused on patients whose cancers are driven by the hormone estrogen, the most common form of breast cancer worldwide. Today, many such patients receive CDK4/6 inhibitors in combination with hormone therapy; these drugs work by blocking the cell‑division cycle, thereby stopping cancer cells from multiplying. However, the inhibitors do not work for all patients, and in advanced disease they often lose effectiveness over time.
According to the Garvan study, CDK1 protein activity increased as the cancer became more aggressive. The investigators found a link between higher CDK1 activity and poorer patient outcomes, implying that tumors with higher levels of the protein are more resistant to CDK4/6 inhibitors. The research team cautions that these findings must be tested in larger groups of patients actively being treated with the drug class before CDK1 can be used in clinical decision‑making.
This work fits into an ongoing effort to find biomarkers that can personalize breast‑cancer treatment. By measuring CDK1 activity in a biopsy, clinicians may eventually be able to predict whether a patient’s tumor will respond to CDK4/6 inhibitors, and possibly switch to alternative therapies earlier in the treatment course. The study also opens the possibility of development of drugs that specifically target CDK1, which could offer new options for patients whose tumors demonstrate high CDK1 activity.
Experts note the importance of larger, prospective trials to confirm that CDK1 activity not only correlates with disease aggressiveness but also directly predicts therapeutic resistance. Until such data are available, the protein remains a promising but experimental biomarker. The identification of CDK1 also highlights the broader challenge of managing drug resistance in targeted therapies, an issue that affects many cancer treatments beyond breast cancer.
The Garvan Institute has stated that the discovery “needs to be tested in larger groups of patients treated with CDK4/6 inhibitors, and could eventually open the door to new drugs targeting CDK1.” The study itself was published in the journal Advanced Science, and it marks a step forward in the search for more precise tools to guide breast‑cancer therapy. Future research will determine whether CDK1 testing can be incorporated into routine clinical practice and whether drugs that modulate CDK1 activity will prove effective in patients with aggressive, drug‑resistant tumors.
